Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies

Background: Blood-based tumor mutational burden (bTMB) was recently found to be suboptimal in predicting overall survival (OS) benefits of atezolizumab over docetaxel among patients with advanced non-small cell lung cancer (NSCLC). The maximum somatic allele frequency (MSAF) is an indicator of the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-tong, Seeruttun, Sharvesh Raj, Wu, Xiang-yuan, Wang, Zi-xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929100/
https://www.ncbi.nlm.nih.gov/pubmed/31921683
http://dx.doi.org/10.3389/fonc.2019.01432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929100/
https://www.ncbi.nlm.nih.gov/pubmed/31921683
http://dx.doi.org/10.3389/fonc.2019.01432

Ejemplares similares